Blocking the CXCL12/CXCR4 axis via usage of a CXCR4 receptor antagonist (AMD3100) or antibody in prostate cancer cells, however, decreased tumor size and the population of progenitor cells [208]. Here, CXCL12 is linked to prostate carcinoma.